Handok

002390 · KOSPI · Health Care · SMALL CAP

Back to a net profit.

Handok filed provisional (unaudited) separate results for Q4 2025: revenue of US$93M (+13.64% year on year), operating profit of US$2.89M (from a loss a year earlier) and net income of US$6.71M (from a loss a year earlier).

Earnings(Operating results (preliminary) (fair disclosure))· FILED 2026-02-10· RCEPT 20260210801411

US$93MRevenue
+13.64%Revenue vs a year earlier
US$2.89MOperating profit

Converted at 1 USD ≈ ₩1,458.54 (filing-date rate, 2026-02-10 close)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-10) →

What happened

Handok filed provisional (unaudited) separate results for Q4 2025: revenue of US$93M (+13.64% year on year), operating profit of US$2.89M (from a loss a year earlier) and net income of US$6.71M (from a loss a year earlier).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$93M
Revenue vs a year earlier+13.64%
Operating profitUS$2.89M
Net incomeUS$6.71M
PeriodQ4 2025 (separate)
Filed2026-02-10, Operating results (preliminary) (fair disclosure)
SourceDART rcept 20260210801411 → open original filing

Versions of this filing

  1. 2026-02-10Original (this page)
  2. 2026-03-10Amendment 1

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-10 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.